Skip to main content
Clinical Trials/ITMCTR2000003079
ITMCTR2000003079Not yet recruitingPhase 1

Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)

Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine0 sitesStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 1
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional study

Eligibility Criteria

Ages
18 to 75 (—)
Sex
All

Inclusion Criteria

  • 1) Confirmed or clinically diagnosed patients with the novel coronavirus disease;
  • 2) Those who have been identified by Chinese medicine as pestilence stagnant in Lung;
  • 3) Inpatients aged 18 to 75 years male or female;
  • 4) Volunteer to receive treatment under their own scheme and sign informed consent.

Exclusion Criteria

  • 1) Patients with mild, severe or critical novel coronavirus disease;
  • 2) According to the researcher's judgment, previous or current diseases may affect patients' participation in the trial or influence the outcome of the study, including: malignant disease, autoimmune disease, severe malnutrition, liver and kidney disease, blood disease, nervous system Diseases and endocrine diseases; currently suffering from diseases that seriously affect the immune system, such as: human immunodeficiency virus (HIV) infection, or the blood system, or splenectomy, organ transplantation, etc.;
  • 3) Those who are allergic to the research drug and its main ingredients;
  • 4) pregnant or lactating women;
  • 5) Those who have difficulty taking medicine orally.

Investigators

Sponsor
Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine

Similar Trials